Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate safety and tolerability (establish maximum tolerated dose [MTD], inform the recommended phase 2 dose [RP2D], and identify the dose-limiting toxicities [DLTs]) of MLN7243.


Clinical Trial Description

This is a single arm Phase I study with multiple dosing cohorts as noted below:

- Schedule A: MLN7243 1 mg

- Schedule A: MLN7243 2 mg

- Schedule A: MLN7243 4 mg

- Schedule A: MLN7243 8 mg

- Schedule A: MLN7243 12 mg

- Schedule A: MLN7243 18 mg

- Schedule A: MLN7243 Homozygous Mutant 4 mg ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02045095
Study type Interventional
Source Takeda
Contact
Status Terminated
Phase Phase 1
Start date January 31, 2014
Completion date November 9, 2016

See also
  Status Clinical Trial Phase
Completed NCT00728468 - A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients Phase 1
Completed NCT00445458 - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer Phase 1/Phase 2
Completed NCT00768469 - Study Evaluating Safety And Tolerability, Solid Tumor Phase 1
Recruiting NCT04226066 - Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT04908046 - A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06464055 - A Study of GQ1010 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06231550 - A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors Phase 1
Not yet recruiting NCT05383703 - Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor Phase 1
Recruiting NCT05773937 - A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors Phase 1
Completed NCT04328506 - Bioequivalency Study of CM082 Tablet in Healthy Volunteers Phase 1
Recruiting NCT05886374 - A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT00958724 - Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT05949775 - Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors N/A
Completed NCT00884845 - Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT05277454 - Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT Phase 1
Active, not recruiting NCT03792958 - Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors Phase 1
Withdrawn NCT00997360 - Study of PKI-179 Administered Orally to Subjects With Solid Tumors Phase 1
Completed NCT04126668 - A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers Phase 1
Recruiting NCT05338957 - A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. Phase 1/Phase 2
Recruiting NCT03047811 - The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors N/A